Goldman Sachs maintains Buy on Hologic (NASDAQ: HOLX) price target of $43.00.

Analyst Isaac Ro remains positive on the company noting that while the financial impact from SculpSure will likely be minimal to total revenues, the news of the sizable new contract win is positive as the company business has struggled in since the 2017 acquisition of Cynosure.

For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.

Shares of Hologic closed at $37.69 yesterday.